enVVeno Medical Corporation develops bioprosthetic venous valve devices to treat chronic venous insufficiency (CVI), a degenerative condition affecting millions of patients that causes backward blood flow, blood pooling, and in severe cases venous ulcers that are difficult to heal. The company's lead product, the enVVe System, is a transcatheter-delivered replacement venous valve designed to restore one-way blood flow back to the heart for patients with severe deep venous CVI; no FDA-approved surgical or non-surgical replacement venous valves currently exist for this indication. enVVeno has not yet commercialized products and generates no revenue; the business model depends on securing FDA approval for enVVe through the pre-market approval pathway and subsequent market adoption among vascular surgeons, interventional radiologists, and interventional cardiologists treating a large patient population experiencing significant quality-of-life impairment and substantial healthcare costs.